ICU Medical Inc (ICUI) stock
ICUINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3034% above fair value
$179.27+1.97 (+1.11%)
Close on Nov 13, 2026Market cap $4.48BP/E 74.4Yield –
Earnings
ICU Medical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 18, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$560.40M
+4.4% on a year earlier
Adjusted diluted earnings per share, Q3 FY2026
$2.44
$2.03 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 4 items
Quarterly results
Revenue and earnings per share from each of ICU Medical's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 18, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $560.40M | +4.4% | $1.07 | $2.44 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $551.70M | +0.5% | $0.76 | $2.37 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | $530.20M | -12.3% | $1.20 | $1.97 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 19, 2026during market hours | $540.70M | -14.1% | -$0.64 | $1.91 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $537.00M | -8.8% | -$0.14 | $2.03 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | $548.90M | -8.0% | $1.43 | $2.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025during market hours | $604.70M | +6.7% | -$0.63 | $1.72 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025during market hours | $629.80M | +7.1% | -$0.97 | $2.11 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | $589.10M | +6.5% | -$1.35 | $1.59 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024during market hours | $596.50M | +8.6% | -$0.88 | $1.56 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024during market hours | $566.70M | -0.3% | -$1.63 | $0.96 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024during market hours | $587.90M | +1.7% | -$0.71 | $1.57 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023during market hours | $553.30M | -7.5% | $0.30 | $1.57 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023during market hours | $549.30M | -2.1% | -$0.41 | $1.88 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023during market hours | $568.60M | +4.7% | -$0.41 | $1.74 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023during market hours | $578.00M | +69.8% | -$0.65 | $1.60 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022during market hours | $597.90M | +77.9% | -$0.55 | $1.75 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | $561.00M | – | -$0.31 | $1.37 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | $543.10M | – | -$1.61 | $1.82 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022during market hours | $340.50M | – | $0.91 | $1.82 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021during market hours | $336.10M | – | $1.43 | $2.07 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
ICU Medical's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Adjusted EBITDAnon-GAAP | FY2026 | $415.00M – $435.00M | – | New | Nov 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $415.00M – $435.00M | $400.00M – $430.00M | Raised | Aug 6, 2026 |
| GAAP diluted earnings per shareGAAP | FY2026 | $2.89 – $3.29 | – | New | Nov 5, 2026 |
| GAAP diluted earnings per shareGAAP | FY2026 | $2.89 – $3.29 | $1.03 – $1.74 | Raised | Aug 6, 2026 |
| adjusted diluted earnings per sharenon-GAAP | FY2026 | $8.60 – $9.00 | – | New | Nov 5, 2026 |
| diluted earnings per sharenon-GAAP | FY2026 | $8.60 – $9.00 | $7.75 – $8.45 | Raised | Aug 6, 2026 |
| GAAP net incomeGAAP | FY2026 | $73.00M – $83.00M | – | New | Nov 5, 2026 |
| GAAP net incomeGAAP | FY2026 | $73.00M – $83.00M | $26.00M – $44.00M | Raised | Aug 6, 2026 |
Guidance vs results
The last range ICU Medical gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | diluted earnings per share | $7.35 – $7.65 | $7.76Σ4Q | Above range |
| FY2025 | EPS (GAAP) | -$0.30 – $0.00 | $0.02Σ4Q | Above range |
Guidance history
Every forecast ICU Medical put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Adjusted EBITDA | FY2026 | $415.00M – $435.00M | New |
| Nov 5, 2026 | adjusted diluted earnings per share | FY2026 | $8.60 – $9.00 | New |
| Nov 5, 2026 | GAAP diluted earnings per share | FY2026 | $2.89 – $3.29 | New |
| Nov 5, 2026 | GAAP net income | FY2026 | $73.00M – $83.00M | New |
| Aug 6, 2026 | Adjusted EBITDA | FY2026 | $415.00M – $435.00M | Raised |
| Aug 6, 2026 | diluted earnings per share | FY2026 | $8.60 – $9.00 | Raised |
| Aug 6, 2026 | GAAP diluted earnings per share | FY2026 | $2.89 – $3.29 | Raised |
| Aug 6, 2026 | GAAP net income | FY2026 | $73.00M – $83.00M | Raised |
| Feb 19, 2026 | adjusted EBITDA | FY2026 | $400.00M – $430.00M | New |
| Feb 19, 2026 | adjusted EPS | FY2026 | $7.75 – $8.45 | New |
| Feb 19, 2026 | GAAP net earnings per share | FY2026 | $1.03 – $1.74 | New |
| Feb 19, 2026 | GAAP net income | FY2026 | $26.00M – $44.00M | New |
| Nov 6, 2025 | adjusted EBITDA | FY2025 | $395.00M – $405.00M | New |
| Nov 6, 2025 | diluted earnings per share | FY2025 | $7.35 – $7.65 | New |
| Nov 6, 2025 | GAAP diluted loss per share | FY2025 | -$0.30 – $0.00 | New |
| Nov 6, 2025 | GAAP net loss | FY2025 | -$8.00M – $0 | New |
| Aug 7, 2025 | adjusted EBITDA | FY2025 | $380.00M – $390.00M | Lowered |
| Aug 7, 2025 | diluted earnings per share | FY2025 | $6.85 – $7.15 | Narrowed |
| Aug 7, 2025 | GAAP diluted loss per share | FY2025 | -$1.68 – -$1.38 | Narrowed |
| Aug 7, 2025 | GAAP net loss | FY2025 | -$43.00M – -$35.00M | New |
| Feb 27, 2025 | adjusted EBITDA | FY2025 | $395.00M – $425.00M | New |
| Feb 27, 2025 | adjusted EPS | FY2025 | $6.55 – $7.25 | New |
| Feb 27, 2025 | GAAP net loss per share | FY2025 | -$1.81 – -$1.11 | New |
| Nov 12, 2024 | adjusted EBITDA | FY2024 | $355.00M – $365.00M | Raised |
| Nov 12, 2024 | diluted earnings per share | FY2024 | $5.40 – $5.70 | Raised |
| Nov 12, 2024 | GAAP diluted loss per share | FY2024 | -$5.28 – -$4.98 | Lowered |
| Nov 12, 2024 | GAAP net loss | FY2024 | -$130.00M – -$122.00M | Lowered |
| Aug 7, 2024 | adjusted EBITDA | FY2024 | $345.00M – $365.00M | Narrowed |
| Aug 7, 2024 | diluted earnings per share | FY2024 | $4.95 – $5.35 | Raised |
| Aug 7, 2024 | GAAP diluted loss per share | FY2024 | -$4.78 – -$4.38 | Raised |
| Aug 7, 2024 | GAAP net loss | FY2024 | -$118.00M – -$108.00M | Lowered |
| May 7, 2024 | Adjusted EBITDA | FY2024 | $330.00M – $370.00M | Reaffirmed |
| May 7, 2024 | Adjusted diluted earnings per share | FY2024 | $4.40 – $5.10 | Reaffirmed |
| May 7, 2024 | GAAP diluted loss per share | FY2024 | -$5.16 – -$4.46 | Lowered |
| Feb 27, 2024 | adjusted EBITDA | FY2024 | $330.00M – $370.00M | New |
| Feb 27, 2024 | adjusted diluted EPS | FY2024 | $4.40 – $5.10 | New |
| Feb 27, 2024 | GAAP diluted loss per share | FY2024 | -$3.57 – -$2.87 | New |
| Feb 27, 2024 | GAAP net loss | FY2024 | -$88.00M – -$71.00M | New |
| Aug 7, 2023 | adjusted EBITDA | FY2023 | $375.00M – $405.00M | Lowered |
| Aug 7, 2023 | adjusted diluted earnings per share | FY2023 | $6.00 – $6.85 | Narrowed |
| Aug 7, 2023 | GAAP diluted loss per share | FY2023 | -$2.42 – -$1.57 | Narrowed |
| Aug 7, 2023 | GAAP net loss | FY2023 | -$59.00M – -$38.00M | Narrowed |
| Feb 27, 2023 | adjusted EBITDA | FY2023 | $375.00M – $425.00M | New |
| Feb 27, 2023 | adjusted diluted EPS | FY2023 | $5.75 – $7.25 | New |
| Feb 27, 2023 | GAAP diluted loss per share | FY2023 | -$3.00 – -$1.50 | New |
| Feb 27, 2023 | GAAP net loss | FY2023 | -$73.00M – -$37.00M | New |
| Nov 7, 2022 | adjusted EBITDA | FY2022 | $350.00M – $370.00M | Reaffirmed |
| Nov 7, 2022 | adjusted diluted earnings per share | FY2022 | $6.20 – $6.80 | Reaffirmed |
| Nov 7, 2022 | GAAP diluted loss per share | FY2022 | -$3.93 – -$3.35 | New |
| Nov 7, 2022 | GAAP net loss | FY2022 | -$95.00M – -$81.00M | New |
| Aug 8, 2022 | adjusted EBITDA | FY2022 | $350.00M – $370.00M | Lowered |
| Aug 8, 2022 | adjusted diluted earnings per share | FY2022 | $6.20 – $6.80 | Lowered |
| Feb 24, 2022 | adjusted EBITDA | FY2022 | $450.00M – $500.00M | New |
| Feb 24, 2022 | adjusted diluted EPS | FY2022 | $9.00 – $10.50 | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases ICU Medical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?